FMP
Regencell Bioscience Holdings Limited
RGC
NASDAQ
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
12.62 USD
-1.47 (-11.65%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.63B
5.02B
6.13B
5.23B
5.84B
7.45B
9.5B
12.11B
15.44B
19.69B
Revenue %
-
90.96
22.05
-14.65
11.64
27.5
27.5
27.5
27.5
Operating Cash Flow
425.03M
595.15M
676.06M
705.42M
739.38M
970.81M
1.24B
1.58B
2.01B
2.57B
Operating Cash Flow %
16.16
11.85
11.03
13.48
12.66
13.03
13.03
13.03
13.03
Cap Ex
-100.46M
-191.9M
-248.36M
-253.49M
-277.69M
-317.11M
-404.32M
-515.5M
-657.26M
-838.01M
Cap Ex %
-3.82
-3.82
-4.05
-4.84
-4.75
-4.26
-4.26
-4.26
-4.26
Free Cash Flow
324.58M
403.25M
427.7M
451.93M
461.7M
653.7M
833.46M
1.06B
1.35B
1.73B
Weighted Average Cost Of Capital
Price
82.53
Beta
Diluted Shares Outstanding
85.24M
Costof Debt
5.09
Tax Rate
After Tax Cost Of Debt
3.84
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
2.08B
Total Equity
7.04B
Total Capital
9.11B
Debt Weighting
22.78
Equity Weighting
77.22
Wacc
9.42
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.63B
5.02B
6.13B
5.23B
5.84B
7.45B
9.5B
12.11B
15.44B
19.69B
Operating Cash Flow
425.03M
595.15M
676.06M
705.42M
739.38M
970.81M
1.24B
1.58B
2.01B
2.57B
Cap Ex
-100.46M
-191.9M
-248.36M
-253.49M
-277.69M
-317.11M
-404.32M
-515.5M
-657.26M
-838.01M
Free Cash Flow
324.58M
403.25M
427.7M
451.93M
461.7M
653.7M
833.46M
1.06B
1.35B
1.73B
Wacc
9.42
9.42
9.42
9.42
9.42
Pv Lfcf
597.4M
696.09M
811.08M
945.07M
1.1B
Sum Pv Lfcf
4.15B
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.42
Free Cash Flow T1
1.76B
Terminal Value
23.74B
Present Terminal Value
15.13B
Intrinsic Value
Enterprise Value
19.28B
Net Debt
2.08B
Equity Value
17.21B
Diluted Shares Outstanding
85.24M
Equity Value Per Share
201.85
Projected DCF
201.85 0.591%
